The long-term objective of this application is the prevention of autoimmune mediated Type 1 diabetes mellitus. Many promising interventions must be tested in a safe and efficient manner to achieve this goal. A well-organized cooperative network of capable institutes will greatly facilitate the prompt completion of multiple clinical trials needed to select from among these potential interventions. The application responds to the RFA proposing the Type 1 Diabetes TrialNet.
The specific aims of the first section, TrialNet at Stanford University, are first, to continue and to improve the infrastructure essential to completing the current Diabetes Prevention Trial - Type 1 (DPT-1) protocols; and second, to conduct new multi-center clinical trials directed at the prevention of Type 1 diabetes mellitus (T1DM) by transforming the current DPT-1 center into a TrialNet center. This section reviews our seven-year experience as a DPT-1 national center in the middle of a high population density geographic location. We highlight our plans for extending and improving recruitment and retention activities for the next seven years. These plans include both completing the current DPT-1 protocol and conducting the expected upcoming pilot trials in subjects with new onset T1DM. These pilot trials will guide the selection of appropriate interventions for any future definitive clinical trials for the prevention of T1DM in high-risk subjects. The second section, DNA Vaccination With Insulin B:9-23, articulates our proposed intervention trial to study this novel therapy in subjects with T1DM. Phase 1 safety studies using DNA vaccination have demonstrated no significant adverse events, so that it is now reasonable to consider this innovative approach as a possible therapy for diabetes prevention. We propose to initiate Phase 1 safety studies followed by Phase 2 efficacy studies using DNA vaccination with insulin B:9-23.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01DK061042-05
Application #
6927257
Study Section
Special Emphasis Panel (ZDK1-GRB-C (O1))
Program Officer
Leschek, Ellen W
Project Start
2001-09-29
Project End
2008-06-30
Budget Start
2005-07-01
Budget End
2006-06-30
Support Year
5
Fiscal Year
2005
Total Cost
$771,086
Indirect Cost
Name
Stanford University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Ismail, Heba M; Xu, Ping; Libman, Ingrid M et al. (2018) The shape of the glucose concentration curve during an oral glucose tolerance test predicts risk for type 1 diabetes. Diabetologia 61:84-92
Culina, Slobodan; Lalanne, Ana Ines; Afonso, Georgia et al. (2018) Islet-reactive CD8+ T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors. Sci Immunol 3:
Vecchio, Federica; Lo Buono, Nicola; Stabilini, Angela et al. (2018) Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes. JCI Insight 3:
Redondo, Maria J; Steck, Andrea K; Sosenko, Jay et al. (2018) Transcription Factor 7-Like 2 (TCF7L2) Gene Polymorphism and Progression From Single to Multiple Autoantibody Positivity in Individuals at Risk for Type 1 Diabetes. Diabetes Care 41:2480-2486
Sanda, Srinath; Type 1 Diabetes TrialNet Study Group (2018) Increasing ICA512 autoantibody titers predict development of abnormal oral glucose tolerance tests. Pediatr Diabetes 19:271-276
Yeo, Lorraine; Woodwyk, Alyssa; Sood, Sanjana et al. (2018) Autoreactive T effector memory differentiation mirrors ? cell function in type 1 diabetes. J Clin Invest 128:3460-3474
Redondo, Maria J; Geyer, Susan; Steck, Andrea K et al. (2018) A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. Diabetes Care 41:1887-1894
Greenbaum, Carla J; Speake, Cate; Krischer, Jeffrey et al. (2018) Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience. Diabetes 67:1216-1225
Haller, Michael J; Schatz, Desmond A; Skyler, Jay S et al. (2018) Low-Dose Anti-Thymocyte Globulin (ATG) Preserves ?-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. Diabetes Care 41:1917-1925
Redondo, Maria J; Geyer, Susan; Steck, Andrea K et al. (2018) TCF7L2 Genetic Variants Contribute to Phenotypic Heterogeneity of Type 1 Diabetes. Diabetes Care 41:311-317

Showing the most recent 10 out of 75 publications